Bicycle therapeutics announces four abstracts accepted for presentation at the esmo congress 2024

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced the acceptance of four abstracts for poster presentation at the european society for medical oncology (esmo) congress 2024, taking place september 13-17 in barcelona. poster presentation details: title: bt8009 monotherapy in enfortumab vedotin-naÏv.
BCYC Ratings Summary
BCYC Quant Ranking